1-20 of 30
Weijun Fu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

PI3Kδ Inhibitor Linperlisib As a ≥ 3-Line Treatment for Relapsed or Refractory Follicular Lymphoma: A Subgroup Analysis of a Phase II, Single-Arm, Open-Label Trial

Hang Su, Tingyu Wang, Xiuhua Sun, Lihua Qiu, Junning Cao, Zhiming Li, Yuqin Song, Li Zhang, Dengju Li, Huijing Wu, Wei Zhang, Junmin Li, Keshu Zhou, Hui Zhou, Yu Yang, Zhifeng Li, Hong Cen, Zhen Cai, Zhihui Zhang, Weijun Fu, Jie Jin, IV, Fei Li, Weixin Wu, Xuekui Gu, Weiliang Zhu, Lihong Liu, Zengjun Li, Shuhua Yi, Hanying Bao, Zusheng Xu, Lugui Qiu
Journal: Blood
Blood (2023) 142 (Supplement 1): 1677.
https://doi.org/10.1182/blood-2023-178710
Published: 2023
Journal Articles

Ixazomib Maintenance Therapy in Chinese Patients with Newly Diagnosed Multiple Myeloma Not Treated with Stem Cell Transplantation: A Single-Arm, Open-Label Study

Weijun Fu, Juan Du, Lu Zhong, Lijuan Chen, Jian Li, Donghua Zhang, Jianqing Mi, Yan Liu, Sheng Wu, Richard Labotka, Cong Li, Wenhan Jiang, Wenming Chen
Journal: Blood
Blood (2023) 142 (Supplement 1): 6735.
https://doi.org/10.1182/blood-2023-181444
Published: 2023
Journal Articles

Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Asian Patients with Newly Diagnosed Multiple Myeloma: Final Analysis of the Phase 3 Octans Study

Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Gang An, Je-Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, Chor Sang Chim, Robin Carson, Rui Liu, Lingling Wang, Man Zhao, Xi Chen, Canchan Cui, Jian Hou, Jianxiang Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 3388.
https://doi.org/10.1182/blood-2023-181063
Published: 2023
Journal Articles

Dose Adjustments of Linperlisib in Relapsed or Refractory Follicular Lymphoma: A Post-Hoc Analysis of a Pivotal Phase II Study

Fangfang Lyu, Junning Cao, Tingyu Wang, Xiuhua Sun, Lihua Qiu, Hang Su, Zhiming Li, Yuqin Song, Li Zhang, Dengju Li, Huijing Wu, Wei Zhang, Junmin Li, Keshu Zhou, Hui Zhou, Yu Yang, Zhifeng Li, Hong Cen, Zhen Cai, Zhihui Zhang, Weijun Fu, Jie Jin, IV, Fei Li, Weixin Wu, Xuekui Gu, Weiliang Zhu, Lihong Liu, Zengjun Li, Shuhua Yi, Hanying Bao, Zusheng Xu, Lugui Qiu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6140.
https://doi.org/10.1182/blood-2023-180373
Published: 2023
Journal Articles

Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Huixing Zhou, Long Chang, Jing Jia, Jie Ma, Hua Xue, Hao Li, Wenrong Huang, Hebing Zhou, Jingnan Sun, Liping Su, Yanping Ma, Huang Hongming, Hongmei Jing, Zhenling Li, Guangyu Ma, Guohong Su, Jihao Zhou, Biyun Chen, LI Bao, Zhihua Zhang, Lin Yang, Haiping Yang, Yanhong Zhao, Chunyan Sun, Qingming Wang, Qimuge Saiyin, Da Gao, Xiaoxia Chu, Zhenfang Xi, Weiwei Tian, Xuliang Shen, Shi Minxia, Jin Zhang, Yi Chen, Jingbo Xu, Yao Liu, Hongling Peng, Weijun Fu, Jun Luo, Zhenyu Li, Hui-Han Wang, Xiaobo Wang, Xiuli Sun, Jinqiao Zhang, Wei WANG, Yan Yan, Yafei Wang, Xin Du, Yonghuai Feng, Yi Wang, Ying Sun, Liye Zhong, Li Gao, Wenming Chen, Jian Li, Wen Gao
Journal: Blood
Blood (2023) 142 (Supplement 1): 4754.
https://doi.org/10.1182/blood-2023-180736
Published: 2023
Journal Articles

Subgroup Analyses of Progression-Free Survival from the Phase 3 Octans and Alcyone Studies in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib, Melphalan, and Prednisone with or without Daratumumab

Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Gang An, Je-Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, Chor Sang Chim, Paula Rodriguez Otero, Meletios A. Dimopoulos, Tomoaki Fujisaki, Jae Hoon Lee, Susan Wroblewski, Fredrik Borgsten, Robin Carson, Rui Liu, Man Zhao, Tingting Wu, Xi Chen, Canchan Cui, Jian Hou, Jianxiang Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 2006.
https://doi.org/10.1182/blood-2023-180809
Published: 2023
Journal Articles

Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) Alone in Chinese Patients with Relapsed/Refractory Multiple Myeloma: Final Analysis of the Phase 3 Lepus Study

Weijun Fu, Xue Gai, Weiping Liu, Xi Chen, Canchan Cui, Jin Lu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6719.
https://doi.org/10.1182/blood-2023-181025
Published: 2023
Journal Articles

Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kδ Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular Lymphoma

Tingyu Wang, Xiuhua Sun, Lihua Qiu, Hang Su, Junning Cao, Zhiming Li, Yuqin Song, Li Zhang, Dengju Li, Huijing Wu, Wei Zhang, Junmin Li, Keshu Zhou, Hui Zhou, Yu Yang, Zhifeng Li, Hong Cen, Zhen Cai, Zhihui Zhang, Weijun Fu, Jie Jin, IV, Fei Li, Weixin Wu, Xuekui Gu, Weiliang Zhu, Lihong Liu, Zengjun Li, Shuhua Yi, Hanying Bao, Zusheng Xu, Lugui Qiu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6145.
https://doi.org/10.1182/blood-2023-177820
Published: 2023
Journal Articles

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

Clinical Trials & Observations
Bruno Paiva, Irene Manrique, Meletios A. Dimopoulos, Francesca Gay, Chang-Ki Min, Sonja Zweegman, Ivan Špička, Raphael Teipel, María-Victoria Mateos, Nicola Giuliani, Michele Cavo, Christine Rojas Hopkins, Weijun Fu, Kaveri Suryanarayan, Alexander Vorog, Cong Li, Bingxia Wang, Jose Estevam, Richard Labotka, Ajeeta B. Dash
Journal: Blood
Blood (2023) 141 (6): 579–591.
https://doi.org/10.1182/blood.2022016782
Published: 2023
Includes: Supplemental data
Journal Articles

Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up

Jian-Qing Mi, Wanhong Zhao, Hongmei Jing, Weijun Fu, Jianda Hu, Lijuan Chen, Yiwen Zhang, Dan Yao, Hui Li, Jordan M Schecter, Fan Yang, Huabin Sun, Sen Hong Zhuang, Da Xu, Tracy Luo, Xiaohu Fan, Ting Niu, Jie Jin, Sai-Juan Chen
Journal: Blood
Blood (2022) 140 (Supplement 1): 7542–7544.
https://doi.org/10.1182/blood-2022-159185
Published: 2022
Journal Articles

Phase I Open-Label Single-Arm Study of BCMA/CD19 Dual-Targeting FasTCAR-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

Juan Du, Weijun Fu, Jing Lu, Wanting Qiang, Haiyan He, Jin Liu, Ying Yang, Zhongyuan Feng, Lina Jin, Xiaoqiang Fan, Jia Liu, Qi Zhang, Lianjun Shen, Lihong Weng, Wei Cao
Journal: Blood
Blood (2022) 140 (Supplement 1): 889–890.
https://doi.org/10.1182/blood-2022-162295
Published: 2022
Journal Articles

Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients with Renal Insufficiency: A Systematic Review and Meta-Analysis

Weijun Fu, Hua Jiang, Lu Li, Mingzhao Gao, Jia Mi, Canchan Cui
Journal: Blood
Blood (2022) 140 (Supplement 1): 12525–12526.
https://doi.org/10.1182/blood-2022-157263
Published: 2022
Journal Articles

Phase 2 March Study: ATG-010 Plus Low Dose Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI)

Lugui Qiu, Weijun Fu, Zhongjun Xia, Zhengzheng Fu, Wenming Chen, Chunkang Chang, Baijun Fang, Gang An, Yongqiang Wei, Zhen Cai, Sujun Gao, Jianyu Weng, Lijuan Chen, Hongmei Jing, Li Fei, Zhuogang Liu, Xiequn Chen, Jing Liu, Yang Yu, Aihua Wang, Yijun Yang, Zhinuan Yu, Kevin Lynch
Journal: Blood
Blood (2021) 138 (Supplement 1): 4770.
https://doi.org/10.1182/blood-2021-145282
Published: 2021
Journal Articles

ATG-010 Plus Low-Dose Dexamethasone (Sd) in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Received Chimeric Antigen Receptor T-Cell (CAR-T)

Weijun Fu, Lugui Qiu, Zhongjun Xia, Zhengzheng Fu, Wenming Chen, Chunkang Chang, Baijun Fang, Gang An, Yongqiang Wei, Zhen Cai, Sujun Gao, Jianyu Weng, Lijuan Chen, Hongmei Jing, Li Fei, Zhuogang Liu, Xiequn Chen, Jing Liu, Yang Yu, Aihua Wang, Zhinuan Yu, Yijun Yang, Kevin Lynch
Journal: Blood
Blood (2021) 138 (Supplement 1): 4778.
https://doi.org/10.1182/blood-2021-146784
Published: 2021
Journal Articles

Daratumumab, Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: Pooled Analysis of Octans and Alcyone

Jian Hou, Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Gang An, Je-Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, CS Chim, Paula Rodriguez-Otero, Meletios A. Dimopoulos, Tomoaki Fujisaki, Jae Hoon Lee, Susan Wroblewski, Robin Carson, Ming Qi, Jianping Wang, Yang Song, Bin Jia, Xue Yang, Wenyu Liu, Yunan Li, Renyi Zhang, Jianxiang Wang
Journal: Blood
Blood (2021) 138 (Supplement 1): 1661.
https://doi.org/10.1182/blood-2021-146974
Published: 2021
Journal Articles

Progression-Free Survival Outcomes By Response Status for Bortezomib, Melphalan, and Prednisone with or without Daratumumab in Newly Diagnosed Multiple Myeloma: Pooled Subgroup Analysis of Octans and Alcyone

Jianxiang Wang, Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Gang An, Je-Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, CS Chim, Paula Rodriguez-Otero, Anna Marina Liberati, Hiroyuki Takamatsu, Jae Hoon Lee, Meletios A. Dimopoulos, Susan Wroblewski, Robin Carson, Ming Qi, Jianping Wang, Yang Song, Bin Jia, Xue Yang, Wenyu Liu, Yunan Li, Renyi Zhang, Jian Hou
Journal: Blood
Blood (2021) 138 (Supplement 1): 1648.
https://doi.org/10.1182/blood-2021-148937
Published: 2021
Journal Articles

Clinical Results of a Multicenter Study of the First-in-Human Dual BCMA and CD19 Targeted Novel Platform Fast CAR-T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

Hua Jiang, MD, Baoxia Dong, MD PhD, Li Gao, Li Liu, MD, Jian Ge, Aili He, Juan Du, Jr., MD, Lu Li, Jing Lu, MD, Xiequn Chen, Yi Zhao, Yu Han, Yuezhang Chen, Yuesheng Xu, Hua Zhang, Jiaping He, Huan Shi, Cong Han, Xun Ye, Zhenguang Wang, Jia Liu, Lianjun Shen, MD, Wei Cao, Martina Sersch, MD PhD, Weijun Fu, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 25–26.
https://doi.org/10.1182/blood-2020-138614
Published: 2020
Journal Articles

Plasma Cell-Free DNA Chromosomal Instability As Surrogate Biomarker of Treatment Response and Minimal Residual Diseases for Multiple Myeloma

Juan Du, Jr., MD, Baoan Chen, MDPhD, Wanting Qiang, Yanchun Jia, Jing Lu, MD, Lu Li, Jing Liu, Hua Jiang, MD, Ziliang Qian, Weijun Fu, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 29.
https://doi.org/10.1182/blood-2020-138783
Published: 2020
Journal Articles

Prognostic Importance of Measurable Residual Disease (MRD) Kinetics and Progression-Free Survival (PFS) Benefit in MRD+ Patients (Pts) with Ixazomib Vs Placebo As Post-Induction Maintenance Therapy: Results from the Multicenter, Double-Blind, Phase 3 TOURMALINE-MM4 Trial in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Pts

Bruno Paiva, PhD, Irene Manrique, PhD, Nicola Giuliani, Michele Cavo, Christine Rojas, MD, Weijun Fu, MD PhD, María-Victoria Mateos, MD PhD, Meletios A Dimopoulos, Alexander Vorog, MD, Cong Li, PhD, Bingxia Wang, PhD, Richard J Labotka, MD, Ajeeta B Dash, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–21.
https://doi.org/10.1182/blood-2020-136105
Published: 2020
Journal Articles

Daratumumab, Bortezomib, Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory (RR) Multiple Myeloma (MM): Pooled Subgroup Analysis of Lepus and Castor

Jin Lu, Weijun Fu, MDPhD, Wei Li, MD, Jianda Hu, MDPhD, Gang An, MD PhD, Yafei Wang, Chengcheng Fu, Lijuan Chen, MDPhD, Jie Jin, MD PhD, Xinan Cen, Zheng Ge, MDPhD, Zhen Cai, MD PhD, Ting Niu, MD PhD, Andrew Spencer, DM, Katja Weisel, MD, María-Victoria Mateos, MD PhD, Ajay Nooka, MDMPH, Ming Qi, MD PhD, Steven Sun, Xue Gai, Weiping Liu, Xue Yang, Xiaojun Huang
Journal: Blood
Blood (2020) 136 (Supplement 1): 38–41.
https://doi.org/10.1182/blood-2020-136108
Published: 2020